logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12778933 B1

PDFFull Text
Date of Patent:
Nov. 03, 2026

Filed:

Jun. 30, 2023

Treatment of glaucoma using endothelin receptor antagonists

Applicant:

Perfuse Therapeutics, Inc., San Francisco, CA (US);

Inventors:

Sevgi Gurkan, Belmont, CA (US);

David Floyd, Pennington, NJ (US);

Assignee:

Perfuse Therapeutics, Inc., South San Francisco, CA (US);

Attorney:

Goodwin Procter LLP

Primary Examiner:

Bethany P Barham

Assistant Examiner:

Peter undefined Anthopolos

Int. Cl.
CPC ...
A61K 31/422 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/19 (2006.01); A61K 31/36 (2006.01); A61K 31/4025 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/40 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/422 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/0051 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/19 (2013.01); A61K 31/36 (2013.01); A61K 31/4025 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/40 (2013.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01);
Abstract

The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Find Patent Forward Citations

Quick Actions:

Gurkan, Sevgi. (2026). Treatment of glaucoma using endothelin receptor antagonists (U.S. Patent No. 12778933). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12778933

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…